Background and study aims: We aimed to determine the feasibility of obtaining selective fluorescence of precancerous/cancerous
lesions in the colon with a new fluorescence video endoscope system in combination
with the selective photosensitizer precursor hexaminolevulinate (HAL), and to carry
out a dose-finding study with evaluation of the optimal dose and application time.
Patients and methods: 12 patients with colorectal lesions underwent sensitization with locally applied
HAL enemas in two concentrations (0.8 mmol and 1.6 mmol). The examination was conducted
either 30 or 60 minutes after rectal administration of the sensitizer, using a special
light source capable of delivering either white or blue excitation light. Red fluorescence
induced by illumination with blue light was detected via a prototype fluorescence
video colonoscope. Biopsies were taken from suspicious areas found with white or blue
light. Corresponding endoscopic, fluorescence, and microscopic findings were compared.
Results: Using histological findings as the gold standard, 52/53 of the premalignant/malignant
lesions showed red fluorescence under the photodynamic diagnosis (PDD) examination;
38/53 were detected with white-light endoscopy. The PDD mode showed 28 % more polyps
than did white-light endoscopic imaging. The greatest fluorescence intensity in precancerous
lesions was found with retention for 60 minutes of 500 ml of 1.6 mmol HAL.
Conclusions: Administration of HAL enema induces selective lesion fluorescence and increases the
lesion detection rate in patients with colorectal adenoma and early carcinoma.
References
- 1
Pickhardt P J, Nugent P A, Mysliwiec P A. et al .
Location of adenomas missed by optical colonoscopy.
Ann Intern Med.
2004;
141
352-359
- 2
Kiesslich R, Moenk S, Reinhardt K. et al .
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia
and colon cancer in ulcerative colitis.
Gastroenterology.
2003;
124
880-888
- 3
Hurlstone D P, Cross S S, Slater R. et al .
Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial
of pan-colonic versus targeted chromoscopy.
Gut.
2004;
53
376-380
- 4
Messmann H, Endlicher E, Freunek G. et al .
Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative
colitis using systemic or local 5-aminolaevulinic acid sensitisation.
Gut.
2003;
52
1003-1007
- 5
Mayinger B, Guenther K, Horner P. et al .
Diagnosis of rectal cancer and adenoma with light-induced autofluorescence spectroscopy.
J Photochem Photobiol B.
2003;
70
13-20
- 6
Mayinger B, Reh H, Hochberger J, Hahn E G.
Endoscopic photodynamic diagnosis: oral aminolevulinic acid is a marker of GI cancer
and dysplastic lesions.
Gastrointest Endosc.
1999;
50
242-246
- 7
Mayinger B, Neidhardt S, Reh H. et al .
Fluorescence induced with 5-aminolevulinic acid for the endoscopic detection and follow-up
of esophageal lesions.
Gastrointest Endosc.
2001;
54
572-578
- 8
Endlicher E, Knuechel R, Hauser T. et al .
Endoscopic fluorescence detection of low and high grade dysplasia in Barrett’s oesophagus
using systemic or local 5-aminolaevulinic acid sensitisation.
Gut.
2001;
48
314-319
- 9
Messmann H, Endlicher E, Freunek G. et al .
Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative
colitis using systemic or local 5-aminolaevulinic acid sensitisation.
Gut.
2003;
52
1003-1007
- 10
Ochsenkuhn T, Tillack C, Stepp H. et al .
Low frequency of colorectal dysplasia in patients with long-standing inflammatory
bowel disease colitis; detection by fluorescence endoscopy.
Endoscopy.
2006;
38
477-482
- 11
Endlicher E, Rümmele P, Hausmann F. et al .
Detection of dysplastic lesions by fluorescence in a model of chronic colitis in rats
after local application of 5-aminolevulinic acid and its esterified derivatives.
Photochem Photobiol.
2004;
79
189-192
- 12
Endlicher E, Gelbmann C M, Knüchel R. et al .
Hexaminolevulinate-induced fluorescence endoscopy in patients with rectal adenoma
and cancer: a pilot study.
Gastrointest Endosc.
2004;
60
449-454
- 13
Klem B, Lappin G, Nicholson S. et al .
Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration
in human volunteers.
J Clin Pharmacol.
2006;
46
456-460
1 Both authors contributed equally.
B. Mayinger, MD, PhD
Department of Medicine II,
Hospital Munich-Pasing
Steinerweg 5
81241 Munich
Germany
Fax: +49-89-88922411
Email: brigitte.mayinger@krankenhaus-pasing.de